Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
A recent consensus document has defined metabolic dysfunction-associated fatty liver disease (MAFLD) as hepatic steatosis together with overweight, diabetes, and/or a combination of other metabolic risk factors. The clinical relevance of this novel diagnosis is unknown among patients with chronic he...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2021
|
| オンライン･アクセス: | https://doi.org/10.1016/j.jhepr.2021.100350 http://www.jhep-reports.eu/article/S2589555921001269/pdf |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|